Alefacept

This page contains recent news articles, when available, and an overview of Alefacept but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Alefacept (when available)

Pharmacology and use:
Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes. For treatment of moderate to severe chronic plaque psoriasis

Mechanism Of Action:
Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.

News Articles on Alefacept

Alefacept for Severe Alopecia Areata - ‎Dec 21, 2009‎
Intervention Alefacept, a US Food and Drug Administration–approved T-cell biologic inhibitor for the treatment of moderate to severe plaque psoriasis. ... Archives of Dermatology

Brand Names/Synonyms:
Alefacept is also known by the following brand names and/or synonymsAmevive; Amevive (Biogen Inc.)

Drug Category:
Alefacept is categorized under the following by the FDA: Immunomodulatory Agents; Immunosuppresants; misc. skin and mucous membrane agents (84:92.00)

Dosage Forms:
POWDER FOR SOLUTION

Absorption:
Not Available

Interactions:
Not Available

Chemical IUPAC Name:
Human LFA-3/IgG1 fusion protein

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.